China faces HIV/AIDS bill of $40B by 2011
China's State Food and Drug Administration has been presented with data from the first clinical trial in the country for a potential vaccine against HIV/AIDS, according to the China Daily government newspaper. The research was carried at a regional disease control center in Nanning, Guangxi Zhuang region, involving 50 healthy volunteers.
$40B HIV/AIDS cost to China
In related news, the Chinese government has issued a statement which estimates the economic cost of HIV/AIDS to the domestic economy at nearly $40.0 billion over the next five years, according to the Xinhua news agency. Zen Yi, the government's chief scientist at the sexually-transmitted disease and AIDS prevention department of the Ministry of Health, has called for an increase in research into antiretroviral vaccination, suggesting that it would cost $125.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze